The Latest Cardiac and Vascular News
– Study met its primary endpoint, achieving statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) compared to placebo at all doses tested – Key secondary endpoints were met including statistically significant reductions in triglycerides and angiopoietin-like-3 (ANGPTL3) at all […]
Olezarsen (IONIS-APOCIII-L Rx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-L Rx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track for year-end Tofersen Phase 3 VALOR study missed primary endpoint; […]
– More than 3 million people in the US have severe hypertriglyceridemia – The CORE Phase 3 clinical study further expands Ionis’ late-stage pipeline and is the second Phase 3 clinical study in Ionis’ broad olezarsen development program – Olezarsen […]
– Ionis-discovered pelacarsen continues to advance as potential first new therapy for Lp(a)-driven cardiovascular disease CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development […]
– Joseph Loscalzo, M.D., Ph.D., appointed chairman of the board – Ionis founder and Executive Chairman Stanley T. Crooke, M.D., Ph.D., retires from the board – Breaux B. Castleman retires from the board – Allene M. Diaz appointed to the […]
On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 5, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights. […]
Phase 1 results for ION449 (AZD8233) demonstrate best-in-class potential, showing potent, dose-dependent PCSK9 reductions of >90% with favorable safety profile CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 […]
– Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular disease CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new […]
CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company’s pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference, to be held virtually Nov. […]
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The […]
